Cord Blood America Salutes President-Elect Obama's Promise to Lift Restrictions on Stem Cell Research
Posted on: Tuesday, 11 November 2008, 06:00 CST
SANTA MONICA, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that the stem cell industry is surging with the news that President-elect Barack Obama intends to use his executive authority to reverse current policies barring certain stem cell research funded by the Federal government.
Administration officials, including John Podesta, who is heading up the transition team for the nation's next President, have told the media that President-elect Obama will reverse the nation's policies on stem cell research as soon as he takes office in January 2009.
"News of increased stem cell research is welcome and has caused a huge increase in interest on Wall Street and elsewhere in stem cell companies," said Matthew Schissler, founder and CEO. "The movement in the markets solidifies that Wall Street is placing a value on stem cell initiatives by the new administration, and moreover, we believe those values will ultimately reflect in stem cell revenue-generating companies like CBAI."
"We are delighted by this interest because we know what role stem cells can play in solving some of our most intractable health care issues, including cancer, diabetes and heart disease," said Mr. Schissler.
Mr. Schissler plans to post a shareholder letter later this month detailing the benefits stem cell therapies going to market and how these game changing events will positively impact the growth of CBAI's stem cell storage services.
About Cord Blood America
Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
Cord Blood America, Inc.
CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,pknopick@eandecommunications.com, for Cord Blood America, Inc.
Web site: http://www.cordblood-america.com/
Source: PRNewswire-FirstCall
Related Articles
- Stem Cell Blood Vessel Source Identified
- Stem Cell Breakthrough: Scientists Say New Procedure Preserves Embryos
- International Stem Cell Names Noted Reproductive Endocrinologist to Scientific Advisory Board
- Stem Cells From Cord Blood Could Become the Standard
- International Stem Cell Corporation Names Edward O. Hunter, Paul V. Maier, to Board of Directors
- Stem Cell Therapy International, Inc. Approved for OTC Bulletin Board and Commenced Trading on May 11, 2007 With Ticker Symbol "SCII"
- Interim Results of Clinical Study Using Aldagen's Product to Isolate Stem Cells From Cord Blood Presented at American Society of Hematology
- Aldagen's Product Used to Isolate Stem Cells From Cord Blood in Human Clinical Study
- ViaCell Reports Encouraging Preclinical Findings of Unrestricted Somatic Stem Cells From Cord Blood
- Leukemia Research Foundation to Host 2nd Annual Conference on Bone Marrow, Stem Cell and Cord Blood Transplants - FREE
 |
 |
User Comments (0)
RSS Feeds